Implanet Announces the Appointment of Brian T. Ennis to Head Its US Subsidiary

Over 30 years of experience in the innovative medical technologies sector with global leaders and growth companies

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:

IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces the appointment of Brian T. Ennis as President of Implanet America. As such, he will head Implanet America and his objective will be to optimize its organisational structure in order to accelerate the JAZZ technology's adoption and growth in this vital market.

Brian T. Ennis, President Implanet America, says: "It is a true privilege to join the Implanet team. I welcome the opportunity to lead the division through an aggressive expansion in the US market. I am quite confident that there is tremendous upside with respect to applying sub-laminar band technology to both the Deformity and Degenerative Spine market Segments."

Ludovic Lastennet, CEO of Implanet, adds: "We are delighted to be able to welcome Brian to lead Implanet's US management team. His experience, strategic vision and managerial skills will enable him to successfully execute Implanet's ambitious growth plan in the United States. During his career, he has proven his ability to meet every new challenge by obtaining outstanding results, whatever the issue. The successes he has recorded throughout his career make Brian a natural leader for our American subsidiary, which now has a solid sales team and more than 25 partner agencies covering 60% of the country. I am confident that Brian will be instrumental in helping us reach incremental major milestones in our development."

Brian brings to Implanet more than 30 years of success in developing and growing medical technology companies. Brian began his career with C.R. Bard in Sales and was rapidly promoted into a marketing management role. After a long tenure at Stryker Corporation in a variety of Marketing and General Management roles in the United States and Europe, he served as the President of International for Wright Medical Group, which specializes in biotechnology and orthopedic devices. Brian was then appointed as the President of Empi, the premier provider of electrotherapeutic medical solutions and pain management successfully leading the company through an integration with a major competitor. Subsequently, Brian was appointed as the President and CEO at Etex Corporation, marshaling the transformation of this start-up specializing in the Research & Development of biomaterials into a profitable and viable high-growth company. Brian has served Implanet as an Independent Board Director and Special Advisor for the past 2 years.

As a reminder, Implanet is to participate at the 2016 BIO CEO Conference Monday and Tuesday, February 8 and 9, 2016, in Waldorf Astoria, New York.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopaedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

Contacts

IMPLANET
Ludovic Lastennet, +33 (0)5 57 99 55 55
CEO
[email protected]
or
NewCap
Investor Relations
Florent Alba, +33 (0)1 44 71 94 94
[email protected]
or
NewCap
Media Relations
Nicolas Merigeau, +33 (0)1 44 71 94 98
[email protected]
or
AlphaBronze
US-Investor Relations
Pascal Nigen, +1 917 385 21 60
[email protected]

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.